Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

This is a source-metadata record last found in a complete check on Sep 25, 2026. It is not a Pependium assessment of safety or effectiveness. Check the original sources for current details, corrections and full methods.

Source status: Exact-ID Europe PMC status checked Sep 25, 2026. No retraction or correction publication-type marker was listed in that response. This does not rule out other updates.

Study metadata

Study type: Original study
Study category (metadata hint): Human
Published: 2020-08-20
Authors: Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS
Journal or registry: JCI insight
Registry study design: Not reported
Registry enrollment: Not reported
Funding agencies: NCATS NIH HHS; National Institutes of Health; NIAID NIH HHS; NIDDK NIH HHS; NICHD NIH HHS
Identifiers: DOI: 10.1172/jci.insight.140134 · PMID: 32701508 · PMCID: PMC7455119
First found: Sep 24, 2026
Last found: Sep 25, 2026

Original sources

View at PubMed ↗View at Europe PMC ↗